论文部分内容阅读
胆管癌是指源于肝外胆管包括肝门区至胆总管下端胆管的恶性肿瘤,发病隐匿,发现肿瘤时大都已是中晚期,预后非常差,肿瘤引起的梗阻性黄疸等一系列并发症,使患者生活质量明显降低。姑息性治疗目前主要是经皮肝穿刺引流(PTCD)或内镜下胆道引流或支架植入,缓解患者的梗阻性黄疸征象,但随着肿瘤的进展,胆道再发梗阻发病率非常高。在胆道引流或支架基础上,行~(125)I粒子腔内植入,在缓解梗阻基础上局部对肿瘤进行治疗,现就~(125)I粒子腔内治疗在中晚期胆管癌的临床应用作一综述。
Cholangiocarcinoma is derived from the extrahepatic bile duct, including the hilar area to the common bile duct of the common bile duct malignant tumor, occult onset, found that most of the tumor is in the advanced stage, the prognosis is very poor, tumor-induced obstructive jaundice and a series of complications, So that patients with significantly lower quality of life. Palliative treatment is currently mainly percutaneous transhepatic drainage (PTCD) or endoscopic biliary drainage or stent implantation to alleviate the symptoms of obstructive jaundice in patients, but as the tumor progresses, the incidence of recurrent biliary obstruction is very high. On the basis of biliary drainage or stents, the intraluminal implantation of ~ (125) I seeds and local treatment of the tumors on the basis of mitigation of obstruction, are now the clinical application of ~ (125) I particle intracavitary therapy in the treatment of advanced cholangiocarcinoma Make a review